摘要
目的比较舒利迭(沙美特罗/丙酸氟替卡松)、舒利迭联合孟鲁司特治疗小儿咳嗽变异性哮喘(CVA)的临床效果。方法将58例CVA患者随机分成观察组和对照组,分别给予舒利迭、舒利迭联合孟鲁司特治疗3个月,观察疗效。结果观察组总有效率为93.1%,对照组总有效率为79.3%,两组疗效比较差异均有统计学意义(P<0.05);观察组在咳嗽缓解和咳嗽消失时间上明显优于对照组(P<0.05);两组治疗前后肺功能指标均有改善(P<0.05)。结论舒利迭联合孟鲁司特较单用舒利迭治疗CVA能更好改善临床症状及肺功能。
Objective To observe the clinical effects of seretide(salmeterol /fluticasone propionate),seretide plus montelukast in treating cough variant asthma(CVA) in children inhalation.Methods 58 cases of children with CVA were randomly divided into two groups respectively treated with seretide or seretide plus montelukast for 3 months.The pulmonary function and clinical symptom before and after treatment were observed in the two groups.Results The overall response rate was 93.1% in the treatment group and 79.3% in the control group.There were statistically significant differences between two groups(P 0.05).The treatment group was obviously superior to the control group in the cough remission and cough disappearance time(P 0.05).The indicators of pulmonary function in the two groups had improved before and after treatment(P 0.05),and the improving pulmonary function in the treatment group was significantly better than that in the control group(P 0.05).Conclusion The improvement of clinical symptoms and pulmonary function appears more rapidly in treating CVA by seretide plus montelukast than by seretide only.
出处
《安徽医药》
CAS
2013年第8期1379-1380,共2页
Anhui Medical and Pharmaceutical Journal